Introduction
============

As defined by the WHO, diabetes comprises a group of metabolic diseases characterized by hyperglycemia caused by impaired insulin effect and/or secretion. The forecasted number of patients suffering from diabetes may appear as high as 366 million in 2030.[@b1-cia-12-653] While more and more diabetic patients become disabled, persistent hyperglycemia[@b2-cia-12-653],[@b3-cia-12-653] brings along even more frequent ophthalmological complications, therefore indicating the surgical treatment of the condition.

The most frequent qualifications for pars plana vitrectomy (PPV) in diabetic patients include recurrent hemorrhage into the vitreous body chamber and vitreoretinal proliferation, also with traction retinal detachment.[@b4-cia-12-653] A continuing development of the new surgical techniques, such as with endolaser photocoagulation and with intraocular endotamponade, improves the chance for prolonging the eye functions.

Unfortunately, in advanced stages of the disease and with age of the patient, it has not been possible to eliminate the risk of glaucoma, which in diabetic patients often proves resistant to the treatment.

One of the examples is the microstent EX-PRESS shunt, made of stainless steel, which is applied to ensure a new path for the removal of the aqueous humor from between the anterior chamber and the space below the Tenon's capsule. It is 3 mm long and 400 µm wide providing filtration through a 50 µm channel. EX-PRESS appears as a promising method for long-term control of the intraocular pressure (IOP), particularly in patients with secondary glaucoma following vitreoretinal surgery, neovascular glaucoma (NVG), and unsuccessful trabeculectomy.[@b5-cia-12-653],[@b6-cia-12-653]

The aim of this study was to evaluate the effectiveness of EX-PRESS implant for the treatment of secondary glaucoma in diabetic patients following PPV 23G with silicon oil or SF6 gas endotamponade.

Materials and methods
=====================

This retrospective analysis comprised 18 patients (19 eyes) aged 65--81 years (mean =72.9; SD =4.7), including 11 females and 7 males with EX-PRESS (Alcon, Novartis AG, Basel, Switzerland) shunt implanted throughout 2013--2014 in St Barbara Regional Specialist Hospital in Sosnowiec. The research was approved by the Research Ethics Committee of the Silesian Medical Chamber in Katowice (resolution number ŚIL/KB/100p/17). Patient consent to review their medical records was not required by the bioethical committee due to the retrospective nature of this study and because patients' information was sufficiently anonymized. All patients had secondary glaucoma and long-term and poorly controlled diabetes. The test group included 1 patient with type 1 diabetes and 17 patients with type 2 diabetes. The patients had earlier undergone full 23G PPV for diabetic complications, such as vitreoretinal proliferation with hemorrhage into the vitreous body chamber (15 patients) and traction retinal detachment (4 patients). A total of 9 eyes with NVG and 10 eyes with non-NVG were included. A topical antiglaucoma treatment did not bring in any effects in all patients. Secondary non-NVG occurred after hemorrhage due to diabetic retinopathy or after PPV with silicone oil endotamponade.

All patients signed informed consent before undergoing any surgical procedure. PPV was performed using type panretinal photocoagulation endolaser photocoagulation and in the peripheral retina, within the 360° range. Silicon oil endotamponade was applied in 12 patients, while SF6 was applied in 6 patients. After 1 month of procedure, silicon oil was removed. All surgeries were performed by one operator. The EX-PRESS shunt was implanted from 3 to 8 months after the PPV under the scleral flap in the upper quadrant. Following the surgery, all the patients locally received the antibiotic and steroid drops as well as mydriatics during 1 month. Despite the maximum pharmacological treatment, the indication for shunt implantation was uncontrolled IOP.

The surgery was considered successful with IOP below 22 mmHg and above 5 mmHg, requiring no additional surgical procedures and no loss in light perception in the operated eye. The need for local drugs to lower IOP was not accepted as failure. Visual acuity was evaluated using best correction, while IOP was measured using Goldmann applanation tonometer 7 days; 1, 3, 6, and 12 months; and a year after the surgery.

Statistical methods applied
---------------------------

For quantitative variables, the calculations comprised mean, standard deviation, median, first quartile, and third quartile. The highest and the lowest value were also quoted. For qualitative variables, number and proportion of patients were given.

Normal distribution of IOP at subsequent observation times and differences in the pressure between particular observation times were evaluated using Shapiro--Wilk test and a histogram. The results from Shapiro--Wilk test did not show the statistical significance for all variables; however, the evaluation of the histogram did not allow to accept normal distribution of a given variable. Therefore, nonparametric tests were used for comparison.

The two-paired samples were compared using Wilcoxon signed-rank test for paired data, while Friedman test was used for multiple measurements (\>2). For two independent samples, Wilcoxon rank test was used. Survival evaluation was performed for "time to failure." Results were presented as Kaplan--Meier curves. Failure was defined as the pressure ≥22 mmHg or ≤5 mmHg.

Evaluation of survival was carried out in subgroups, classified by patients with NVG and secondary diabetic non-NVG. Results of both assays were compared using log-rank test. The significance level of 0.05 was accepted for all tests (the statistically significant scores are marked in bold).

Results
=======

Measurements of the IOP taken before the surgery (T0) as well as after 7 days and 1, 3, 6, and 12 months showed that starting with the very first month following the surgery, the pressure tended to be above the normal level ([Table 1](#t1-cia-12-653){ref-type="table"}). Each time the comparison was done showed a statistically significant score that proves that the values before the surgery are significantly higher than any moment analyzed after the surgery ([Figure 1](#f1-cia-12-653){ref-type="fig"}). The lowest values are 7 days after surgery, then IOP elevates and stabilizes throughout the following. Statistically significant higher results were obtained for the comparison of the 7th day after the surgery with the values recorded 1 month (*P*=0.0065), 3 months (*P*=0.0085), 6 months (*P*=0.001), and 12 months (*P*=0.0272) after the surgery.

The number and proportion of patients with IOP beyond the normal range (≥22) were also assessed. Approximately 7 days after the surgery, the proportion of patients with abnormal IOP was 15.79%, while the proportion after 1 month was as high as 47.37%. The highest proportion of patients with abnormal IOP was recorded after 6 months following the surgery (53.33%) ([Table 2](#t2-cia-12-653){ref-type="table"}).

The comparison of the group of patients with NVG and those with secondary diabetic glaucoma (non-NVG) showed no statistically significant differences between the IOP value before the surgery and the scores after 7 days and 1, 3, 6, and 12 months ([Figure 2](#f2-cia-12-653){ref-type="fig"}). After 7 days, the IOP scores for patients with secondary diabetic glaucoma (nonvascular) were statistically lower than the values for patients with NVG. In contrast, after 1 month, the values of patients with secondary diabetic glaucoma are significantly higher than those of patients with NVG. The mean logMAR best-corrected visual acuity (BCVA) preimplantation was 1.35, which decreased 12 months posttreatment to 1.56 ([Figure 3](#f3-cia-12-653){ref-type="fig"}).

Survival analysis
=================

Survival analysis was also carried out based on the data collected. Failure was defined as the occurrence of IOP beyond the normal range. The observed probability of survival without failure after 1 month following the surgery was 47%. The probability of surviving 3 months without failure was only 32%. The probability of surviving 6 months without failure was 21%, while survival of 12 months was as little as 14% ([Figure 4](#f4-cia-12-653){ref-type="fig"}). The time to failure median was 1 month, and eventually, 16 cases of 19 ended up with a failure.

The survival analysis was also performed in subgroups, dividing between patients with NVG and non-NVG. The patients with NVG showed the probability of survival without failure after 1 month following the surgery to be 67%. The probability of survival of 3 months without failure was 44%. The probability of surviving 6 months without failure was 22%, while the probability for 12 months was 0% ([Figure 5](#f5-cia-12-653){ref-type="fig"}).

The patients with secondary diabetic glaucoma (non-NVG) showed survival probability without failure after 1 month following the surgery to be 90%. The probability of surviving 3 months was 20%. The probability of surviving 6 months without failure was 20%, while the probability for 12 months was again 20% ([Figure 5](#f5-cia-12-653){ref-type="fig"}).

The survival curves for patients with NVG and those with secondary diabetic glaucoma, non-NVG, were compared. No statistically significant differences were obtained for survival distribution in the evaluated groups (statistical value: *χ*^2^=0, degrees of freedom =1, *P*=0.928).

Analysis of drugs
=================

The specification of patients with drugs shows that 1 year after the surgery, 37% of patients need no drugs and as many as 63% received some drugs. Approximately 16% take one drug, and the same proportion was observed with 2 drugs taken 1 year after the surgery, 3 drugs are taken by 25% of patients, and 4 drugs by 5% ([Table 3](#t3-cia-12-653){ref-type="table"}). The calculations were made in the following manner: if a patient was administered 3 drugs after 3 months, then in the following lines (after 6 months and after 1 year), he is still classified as one with 3 drugs (unless the information was available on, eg, addition of another drug after a year; then the patient is included in the column "4 drugs," in the line "after 1 year"). Patients who received no drugs had IOP values lower than 21 mmHg ([Figure 6](#f6-cia-12-653){ref-type="fig"}).

Discussion
==========

Refractory glaucoma is a disease potentially leading to loss of vision, often manifested by difficulties in control of IOP, despite high dosage medication.

The methods of glaucoma treatment such as trabeculectomy, cyclocryotherapy, or cyclophotocoagulation show low success rates, even with relevant premedication administered. The success rate 1 year after the surgery is 62.6% for trabeculectomy,[@b7-cia-12-653] 29%--76% for cyclocryotherapy, with major complications,[@b8-cia-12-653] and 52%--66% for cyclophotocoagulation.[@b9-cia-12-653],[@b10-cia-12-653]

A novel challenge in glaucoma treatment has been EX-PRESS glaucoma filtration device, introduced throughout recent years. During the past 6 years, numerous reports were published, comparing EX-PRESS procedures to trabeculectomy[@b11-cia-12-653]--[@b13-cia-12-653] as well as some reviews.[@b14-cia-12-653] Despite some reports on high risk of complications,[@b15-cia-12-653] EX-PRESS implants ensure higher success rate and less postoperative complications scoring 70.5% and 92.9% for NVG and non-NVG, respectively.[@b16-cia-12-653] A recent report showed high success rate in lowering IOP after the implantation of EX-PRESS in elderly patients.[@b17-cia-12-653]

The major risk factors for EX-PRESS implants have been identified based on the statistical analysis performed. They include non-Caucasian race, diabetes, and earlier glaucoma surgery.[@b14-cia-12-653] EX-PRESS implants are also accompanied by lower rate of inflammation, compared to trabeculectomy, because no tissues are actually removed such as sclerectomy and iridectomy.[@b18-cia-12-653]--[@b20-cia-12-653]

During our study, we applied EX-PRESS implants in patients with both NVG and non-NVG. All the patients had earlier history of diabetes and 23G vitrectomy due to diabetic complications.

The limitation of our study includes a relatively small sample size. The small number of patients reflects high efficacy of modern antiglaucoma drugs. The sudden decrease in IOP 7 days postsurgical treatment compared to 1 month may be attribute to lasting effects of antiglaucoma drugs, despite withdrawal.[@b21-cia-12-653]

Application of the implant exhibited an effect in lower IOP. In all patients, the scores after the procedures were lower than the values taken before (for each of the times evaluated: 7 days and 1, 3, 6, and 12 months). Although the mean IOP values after the surgery were above 22 mmHg with the success rate significantly lower than in patients showing no diabetes. In our opinion, the implant can also be used in elderly diabetic patients.

Conclusion
==========

The comparison of results obtained after the implantation of EX-PRESS shunt to the values documented before the surgery showed statistically significant higher values before the surgery than after the procedures (for each of the times evaluated: 7 days and 1, 3, 6, and 12 months). The values observed 7 days after the surgery were the lowest of all. It was also noted that the scores 1, 3, 6, and 12 months after the surgery are statistically higher than the values 7 days after the surgery. We observed that the pressure was above the normal range already 1 month after the surgery. The comparison of results obtained after 1, 3, 6, and 12 months showed no statistically significant differences throughout the subsequent month after the surgery.

The analysis of survival pointed to 16 cases of failure among the total of 19. The comparison of the subgroups showed eight cases of nine ending with failure (patients with NVG). Among the patients with secondary diabetic glaucoma, 8 cases of 10 ended up with a failure.
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###### 

Basic descriptive statistical values for intraocular pressure at subsequent observation times

  Variable    Mean ± SD (mmHg)   Min   Median   Max   Number of patients
  ----------- ------------------ ----- -------- ----- --------------------
  T0          40.4±8.37          26    40       57    19
  7 days      17.8±4.95          9     17       30    19
  1 month     26.2±10.01         12    21       45    19
  3 months    24.3±8.45          16    21       48    16
  6 months    24.4±9.61          10    23       50    15
  12 months   24.6±11.79         12    21       60    13

**Note:** T0 -- measurement before surgery.

**Abbreviations:** Min, minimum; Max, maximum.

###### 

Number and percentage of patients with IOP beyond normal range (T ≥22)

  Time        Number of patients assessed, N   Number and percentage of patients with T ≥22, n (%)
  ----------- -------------------------------- -----------------------------------------------------
  7 days      19                               3 (15.79)
  1 month     19                               9 (47.37)
  3 months    16                               6 (37.50)
  6 months    15                               8 (53.33)
  12 months   13                               6 (46.15)

**Abbreviation:** IOP, intraocular pressure.

###### 

Number and percentage of patients with given number of drugs at subsequent observation times

  Time of administering medication   Number and percentage of patients with drugs at subsequent times, n (%)                                       
  ---------------------------------- ------------------------------------------------------------------------- ----------- ----------- ----------- ----------
  Drugs instantly                    18 (94.74)                                                                0 (0)       1 (5.26)    0 (0)       0 (0)
  Drugs after 7 days                 17 (89.47)                                                                0 (0)       2 (10.53)   0 (0)       0 (0)
  Drugs after 1 month                15 (78.95)                                                                1 (5.26)    1 (5.26)    2 (10.53)   0 (0)
  Drugs after 3 months               9 (47.37)                                                                 3 (15.79)   3 (15.79)   3 (15.79)   1 (5.26)
  Drugs after 6 months               7 (36.84)                                                                 3 (15.79)   4 (21.05)   4 (21.05)   1 (5.26)
  Drugs after 1 year                 7 (36.84)                                                                 3 (15.79)   3 (15.79)   5 (26.32)   1 (5.26)
